Subsidiary JW Life Science: 2025 revenue +15.9%, net income -34.6%
-
Consolidated 2025 revenue KRW 257.8B (+15.9%), operating profit KRW 33.3B (-7.1%), net income KRW 28.8B (-34.6%)
-
Net income decrease due to base effect of prior-year derivative gains and one-time SG&A costs
-
Total assets KRW 318.6B, total liabilities KRW 97.9B, total equity KRW 220.7B (no capital impairment)
-
Separate: revenue KRW 234.0B, operating profit KRW 31.2B, net income KRW 26.7B
-
Figures are preliminary and unaudited, subject to change
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More (Key Management Matters of Subsidiary)
-
Company: JW Holdings (096760)
-
Submission: JW Holdings Corporation
-
Receipt: 02-02-2026
-
Under KRX KOSPI Market Division